Article
Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).
Journal of acquired immune deficiency syndromes (1999) - 1 Mar 2014
Porter Danielle P, Kulkarni Rima, Fralich Todd, Miller Michael D, White Kirsten L
Abstract excerpt
BACKGROUND: The Single-Tablet Regimen (STaR) study (GS-US-264-0110) is a 96-week phase 3b study evaluating the safety and efficacy of 2 single-tablet regimens, rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF), and efavirenz/emtricitabine/tenofovir DF (EFV/FTC/TDF) in treatment-naive HIV-1-infected subjects. METHODS: Genotypic analyses (population sequencing) of HIV-1 protease and reverse transcriptase were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.